Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland.
Arijita DebPatrik GuggisbergThomas MutschlerKwame Owusu-EduseiGoran BencinaKelly D JohnsonTim IgnacioDaan A R MathijssenVenetia QendriPublished in: Expert review of vaccines (2022)
This evidence justifies the implementation of V114 vaccination among high-risk adults in Switzerland.
Keyphrases